| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | RECRUITING | PHASE1, PHASE2 | 2025-05-31 | 2027-12 | 2027-06 |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | RECRUITING | PHASE1, PHASE2 | 2025-03-24 | 2027-09-30 | 2027-03-31 |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2023-12-08 | 2024-05-22 | 2024-05-22 |
| NCT05887492 | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2023-06-12 | 2026-06 | 2026-01 |
| NCT05732831 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2023-05-26 | 2026-09 | 2026-05 |
| NCT05275478 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-03-23 | 2025-12 | 2025-12 |